Hepatocyte-Targeted Cyclic Peptide LYTACs for PCSK9 Degradation and LDL Cholesterol Metabolic Regulation
treatment significantly depleted circulating PCSK9 and restored lipid profiles. These results demonstrate the robust therapeutic potential of our liver-targeted LYTAC platform for sustained plasma PCSK9 clearance and effective cholesterol regulation.
Authors
- S. Liang
- Yiling Shi
- Wei Gan
- Jiayi Xu (ORCID: https://orcid.org/0000-0003-3465-7927)
- Mingxing Hu
Institutions
- University of Electronic Science and Technology of China (CN)
- China National Nuclear Corporation (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Fourth People's Hospital of Sichuan Province (CN)
- Sichuan Provincial Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- ACS Chemical Biology
- Published
- 2026-03-31
- DOI
- https://doi.org/10.1021/acschembio.6c00029
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- West China Hospital, Sichuan University